MLN0128

sapanisertib · Millennium Pharmaceuticals (Takeda)

Drug timelines are a Plus or Pro feature.

12 regulatory and trial events tracked for MLN0128, covering 2013-08-02 to 2024-01-12. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer [Phase 1, Phase 2]

See pricing